格隆汇9月17日｜ST宁科（维权）公告，因宁夏中科生物科技股份有限公司收到石嘴山市中级人民法院 送达的《民事裁定书》及《决定书》，裁定受理公司重整，并指定公司临时管理人担任管理人。根据 《上海证券交易所股票上市规则》第9.4.1条第(九)项的规定，公司股票将被实施退市风险警示。公司股 票自2025年9月18日开市起停牌一天，将于2025年9月19日开市起复牌，公司股票简称将变更为"*ST宁 科"。 ...

Core Viewpoint - The legal opinion letter confirms that the procedures for convening and holding the 2025 third extraordinary general meeting of Ningxia Zhongke Biotechnology Co., Ltd. comply with relevant laws and regulations, as well as the company's articles of association [1][2][5]. Group 1: Meeting Procedures - The company announced the notice for the third extraordinary general meeting on August 16, 2025, through major financial publications and the Shanghai Stock Exchange website, detailing the meeting's time, location, agenda, and registration methods for shareholders [2][3]. - The meeting utilized a combination of on-site and online voting, with specific time slots for voting through the Shanghai Stock Exchange's systems [3][4]. Group 2: Attendees and Qualifications - The meeting was convened by the company's board of directors, with the chairman, Mr. Fu Jie, presiding over the session [4]. - A total of 256 shareholders or their representatives attended the meeting, holding 220,151,990 shares, which accounted for 32.14% of the total voting shares [4][6]. Group 3: Agenda and Voting Results - The agenda included a proposal regarding the company's new related party relationships and the expected daily related transactions for 2025 [5]. - The voting results showed that 218,998,690 shares (99.4761%) approved the proposal, while 1,105,500 shares (0.5021%) opposed it, and 47,800 shares (0.0218%) abstained [5][6]. Group 4: Conclusion - The legal opinion concludes that all aspects of the meeting, including the convening, attendee qualifications, voting procedures, and results, are in compliance with applicable laws and the company's articles of association [6].

Group 1 - The company is undergoing a pre-restructuring process, with a court decision made on May 30, 2024, to initiate pre-restructuring for Ningxia Zhongke Biological Technology Co., Ltd. and its subsidiary Ningxia Zhongke New Materials Co., Ltd. [4] - The company has identified two potential restructuring investors, with Hunan Chuntou Industrial Development Co., Ltd. being the main investor expected to gain actual control after the restructuring is completed [4][7] - The company plans to manage its related transactions more effectively and has estimated that the total amount of daily related transactions for 2025 will not exceed RMB 110 million [5] Group 2 - The expected daily related transactions include "technical consulting services" and "beneficial debt borrowing," with a total estimated amount of RMB 10 million for beneficial debt borrowing and RMB 200,000 for technical consulting services [5][9] - The company will ensure that all related transactions are conducted at fair market prices and will not harm the interests of the company or its minority shareholders [9][10] - The company maintains independence in its operations, ensuring that related transactions do not affect its independence or create dependency on related parties [10]

Core Points - The legal opinion letter is regarding the second extraordinary general meeting of shareholders of Ningxia Zhongke Biotechnology Co., Ltd. in 2025 [1] - The law firm confirms that the meeting's convening, procedures, and voting processes comply with relevant laws and regulations [2][5] Group 1: Meeting Procedures - The company’s board of directors announced the meeting details, including time, location, and voting methods, through the Shanghai Stock Exchange [2][3] - The meeting utilized both on-site and online voting, with specific time slots for shareholders to cast their votes [3] Group 2: Attendance and Qualifications - The meeting was convened by the board of directors, with Mr. Zhu Canti serving as the chairperson [4] - A total of 293 shareholders or their representatives attended the meeting, representing 240,960,322 shares, which is 35.18% of the total voting shares [4] Group 3: Voting Results - The voting process was conducted in accordance with legal and regulatory requirements, with results verified by the law firm [5][6] - The first proposal received 239,566,822 votes in favor, accounting for 99.4216% of the total votes cast [5] - Subsequent proposals also passed with significant majority support, with the highest approval rate being 99.6722% for one of the proposals [6][7] Group 4: Conclusion - The law firm concludes that all aspects of the meeting, including convening, attendance, and voting, were conducted in compliance with applicable laws and the company's articles of association [7]

Core Viewpoint - The article discusses the announcement of a project by Ningxia Zhongke Biological New Materials Co., Ltd. to produce 110,900 tons of bio-fermentation products annually, highlighting the company's technological upgrades and production capabilities in the bio-manufacturing sector [1]. Project Overview - Project Name: Annual production of 110,900 tons of bio-fermentation products - Construction Unit: Ningxia Zhongke Biological New Materials Co., Ltd. - Nature of Construction: Technological upgrade - Industry Category: C2710 Chemical raw materials and pharmaceutical manufacturing - Investment: 100.89 million yuan - Location: Shizuishan Economic and Technological Development Zone - Land Area: 387,309.18 m², utilizing existing facilities without new land acquisition [2]. Construction Scale - The project includes four flexible production lines: 1. **Long-chain dicarboxylic acid production line**: Annual capacity of 18,000 tons, producing various dicarboxylic acids [3]. 2. **Bio-fermentation functional products production line**: Annual capacity of 5,100 tons, including D-chiro-inositol, coenzyme Q10, and DHA algae oil [4]. 3. **Bio-food production line**: Annual capacity of 63,000 tons, producing calcium propionate and L-malic acid [5]. 4. **Amino acid products production line**: Annual capacity of 24,800 tons, producing various amino acids [6]. Technological Upgrade Scope - The upgrade encompasses fermentation workshops, extraction workshops, refining workshops, drying workshops, liquid bio-fertilizer workshops, tank areas, and power centers [7]. Company Background - Ningxia Zhongke Biological New Materials Co., Ltd. was established on June 2, 2017, with a registered capital of 1.3 billion yuan. The company is involved in the production of feed additives, food additives, fertilizers, and bio-based materials [8]. Financial Performance - The company reported revenue of 345 million yuan and a net loss of 539 million yuan during the reporting period. To address its debt crisis, the company entered pre-restructuring in May 2024, with government support extended until the end of 2024 [9]. - In the first quarter of 2025, the company achieved total revenue of 93.82 million yuan, a year-on-year increase of 74.08%, but still reported a net loss of 64.08 million yuan [11].

Core Viewpoint - The article discusses the recent trend of companies in the Shanghai and Shenzhen stock markets successfully removing risk warnings and improving their operational quality through various measures, reflecting a positive structural improvement in company quality amid regulatory support [3][4][5]. Group 1: Companies Removing Risk Warnings - Several companies, including Hanma Technology, Shuguang Automotive, and Hezhan Energy, have announced the removal of delisting risk warnings, indicating a shift towards improved operational quality [1][2]. - As of April 29, 2025, a total of 7 companies in the Shanghai market and 6 in the Shenzhen market have successfully removed risk warnings, showcasing a trend of companies actively addressing risks and enhancing quality [3]. Group 2: Financial Recovery and Performance Improvement - ST Navigation reported a revenue of 171 million, a year-on-year increase of 685.63%, and a significant reduction in net loss by 79.90%, thus avoiding delisting risk [4]. - ST Hengyu achieved a revenue of 180 million, a year-on-year growth of 320.16%, and turned a profit of 26.74 million, also avoiding delisting risk [4]. - ST Kexin and ST Weiti both reported turning losses into profits in their 2024 annual reports, with ST Kexin's revenue exceeding 300 million [4]. Group 3: Strategies for Risk Mitigation - ST Wentou, facing negative net assets, successfully restructured by divesting inefficient assets, resulting in a positive net asset position and the removal of risk warnings [5]. - ST Xinning improved its financial situation by issuing shares to specific investors and focusing on core operations, leading to a positive net asset status and the removal of risk warnings [6]. - ST Tianchuang and ST Yongyue addressed compliance issues and internal control problems, leading to successful rectifications and the removal of risk warnings [8].